Compare CRSP & RELY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | RELY |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.0B |
| IPO Year | 2016 | 2021 |
| Metric | CRSP | RELY |
|---|---|---|
| Price | $52.09 | $22.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $70.29 | $22.86 |
| AVG Volume (30 Days) | 1.3M | ★ 3.0M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 263.16 |
| EPS | N/A | ★ 1.16 |
| Revenue | $289,590,000.00 | ★ $1,635,147,000.00 |
| Revenue This Year | $807.72 | $21.89 |
| Revenue Next Year | $172.52 | $19.17 |
| P/E Ratio | ★ N/A | $20.78 |
| Revenue Growth | ★ 9169.85 | 29.37 |
| 52 Week Low | $44.12 | $12.08 |
| 52 Week High | $78.48 | $27.48 |
| Indicator | CRSP | RELY |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 35.68 |
| Support Level | $50.45 | $12.55 |
| Resistance Level | $60.41 | $25.16 |
| Average True Range (ATR) | 2.27 | 1.21 |
| MACD | -0.79 | -0.45 |
| Stochastic Oscillator | 4.25 | 6.69 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated from transaction fees charged to customers, and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.